Clinical Trial Update: Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE) [Phase 2]

View source ↗

Summary

Kadence Bio is conducting a Phase 2 study to evaluate KH-001 on intravaginal ejaculatory latency time, patient-reported outcomes, and safety in men with lifelon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ejaculation

Drugs mentioned

• KH-001

Snippet

Sponsor: Kadence Bio | Conditions: Premature Ejaculation | Phase 2 | Status: RECRUITING